The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation

Langenbeck's Archives of Surgery

Volumn 397, Issue 5, 2012, Pages 697-710

  Mehrabi, Arianeb ^a   Esmaeilzadeh, Majid ^a   Fonouni, Hamidreza ^a   Hafezi, Mohammadreza ^a   Rahbari, Nuh N ^a   Golriz, Mohammad ^a   Majlesara, Ali ^a   Rad, Morva Tahmasbi ^a   Sadeghi, Mahmoud ^a   Schmidt, Jan ^a   Ganten, Tom M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

HBIg; Hepatitis B virus; Liver transplantation; Nucleoside nucleotide analogs; Prophylaxis

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ADEFOVIR; ADRENALIN; ANTIVIRUS AGENT; CAF IG ANTI HBS; ENTECAVIR; HEPAGAM; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HYPERHEP BAYHEP; IG ANTI HBS IV; IMMUNOGLOBULIN F(AB) FRAGMENT; LAMIVUDINE; NIULIVA; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; OMRI HEP B; STEROID; TENOFOVIR; UMAN BIG; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; CHEST TIGHTNESS; CHILL; CLINICAL PROTOCOL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SELF ADMINISTRATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPOTENSION; INJECTION SITE REACTION; LEG CRAMP; LIP DISEASE; LIP SWELLING; LIVER TRANSPLANTATION; LOW BACK PAIN; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REINFECTION; REVIEW; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; THROAT DISEASE; TONGUE DISEASE; URTICARIA; VIRUS REPLICATION; VOMITING;

ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LAMIVUDINE; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE CARE; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84863985780     PISSN: 14352443     EISSN: 14352451     Source Type: Journal    
DOI: 10.1007/s00423-011-0795-6     Document Type: Review

References (132)

1. Alter MJ (2003) Epidemiology and prevention of hepatitis B. Semin Liver Dis 23:39-46
2. Perz JF, Farrington LA, Pecoraro C, et al. Estimated global prevalence of hepatitis C virus infection [abstract]. In: Abstracts of the Infectious Diseases Society of America 42nd Annual Meeting, Boston, MA, September 2004.
3. WHO. Hepatitis B fact sheet. http://www.who.int/mediacentre/factsheets/ fs204/en/. Accessed on: February 2005.
4. Viral hepatitis guidelines in hemodialysis and transplantation. Am J Transplant 2004;4(10):72-82
5. Colombo M, Sangiovani A (2003) Etiology, natural history and treatment of hepatocellular carcinoma. Antivir Res 60:145-150
6. Ben Ari Z, Tur-Kaspa R (1997) New trends in liver transplantation for viral hepatitis. Am J Gastroenterol 92:2155
7. Dodson SF, Issa S, Bonham A (1999) Liver transplantation for chronic viral hepatitis. Surg Clin North Am 79:131
8. Rosen HR (2001) Hepatitis B and C in the liver transplant recipient: current understanding and treatment. Liver Transplant 7:S87-S98
9. Faust D, Rabenau HF, Allwin R et al (2003) Cost-effective and safe ambulatory long term immunoprophylaxis with intramuscular instead f intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant 17:254-258
10. Samuel D (2009) The option of liver transplantation for hepatitis B: where are we? Dig Liver Dis 41(Suppl 2):S185-S189
11. Coffin CS, Terrault NA (2007) Management of hepatitis B in liver transplant recipients. J Viral Hepatitis 14(Suppl 1):37-44
12. Pan T, Tang L, Yuan J et al (2007) Recombinant anti-HBsAg fab blocks hepatitis B virus infection after orthotopic liver transplantation. Hepatobilliary Pancreat Dis Int 6:370-375
13. Buti M, Antonio M, Prieto M et al (2003) A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin and lamivudine with long term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 38:811-817
14. Neumann UP, Langrehr JM, Naumann U et al (2002) Impact of HLA compatibilities in patients undergoing liver transplantation for HBV cirrhosis. Clin Transplant 16:122-129
15. Franics MJ, Kane M. Hepatitis B Vaccine, Chapter 10 in Vaccines, 3rd ed. Stanley A. Plotnick and Walter A. Orenstein, eds. W. B. Saunders Company; Philadelphia, 1999 (159-82).
16. Engler SH, Sauer PW, Golling M et al (2001) Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol 13:363-367
17. Eisenbach C, Sauer P, Mehrabi A et al (2006) Prevention of hepatitis B virus recurrence after liver transplantation. Clin Transplant 20(Suppl 17):111-116
18. Riediger C, Berberat PO, Sauer P et al (2007) Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. Nephrol Dial Transplant 22(Suppl 8):viii37-viii46
19. Wang ZX, Ding GS, Fu H et al (2004) Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int 3:345-348
20. Wang ZF, Liu C (2004) Liver retransplantation: indication and outcome. Hepatobiliary Pancreat Dis Int 3:175-178
21. Zhu JP, Zhang TL, Li L et al (2003) Prevention and treatment of hepatitis B recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2:500-503
22. Terrault NA, Zhou S, Combs C et al (1996) Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 24:1327-1333
23. Zheng SS, Wu J, Liang TB et al (2002) Prophylaxis and treatment of hepatitis B virus reinfection following liver transplantation. Hepatobiliary Pancreat Dis Int 1:327-329
24. Samuel D, Feray C, Bismuth H (1997) Hepatitis viruses and liver transplantation. J Gastroenterol Hepatol 12:S335-S341
25. Samuel D, Muller R, Alexander G, Bismuth H et al (1993) Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329(25):1842-1847
26. Hwang S, Lee SG, Ahn CS et al (2008) Prevention of hepatitis B recurrence after living donor liver transplantation: primary highdose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transplant 14:770-778
27. Lu Y, Wang B, Yu L et al (2004) Lamivudine in prevention and treatment of recurrent HBV after liver transplantation. Hepatobiliary Pancreat Dis Int 3:504-507
28. Wang ZF, Zhu ZJ, Shen ZY (2005) Advances in prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Hepatobiliary Pancreat Dis Int 4:509-514
29. Papatheodordis GV, Sevastianos V, Burroughs AK (2003) Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transpl 3:250-258
30. Mas A (2009) Liver transplantation for hepatitis B virus. Preemptive and peri-operative prophylaxis. Dig Liver Dis 41(Suppl 2):S191-S194
31. Shouval D, Samuel D (2000) Hepatitis B immune globulin to prevent HBV graft reinfection following liver transplantation: a concise review. Hepatology 32:1189-1195
32. Van Nunen AB, de Man RA, Heijtink RA et al (2002) Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue? J Viral Hepatitis 9:221-228
33. Liu H, Liu YF (2003) Liver transplantation for patients with viral hepatitis. HBPD Int 2:28-31
34. Baruch Y, Ben-Porath E, Enat R (1994) Immunoprophylaxis with hepatitis B immunoglobulin after liver transplantation, an economical approach. J Hepatol 20:153
35. Hooman N, Rifai K, Hadem J et al (2008) Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transplant 14:435-442
36. Kruger M (2000) European hepatitis B immunoglobulin trials: prevention of recurrent hepatitis B after liver transplantation. Clin Transplant 14(Suppl 2):14
37. Yao FY, Osorio RW, Roberts JP et al (1999) Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transplant Surg 5:491
38. European Medicines Agency: Core SmPC for human normal immunoglobulin for subcutaneous and intramuscular use. CPMP/BPWG/282/00, London 25 July 2002
39. Thürmann PA, Szymanski J, Haffner S et al (2006) Pharmacokinetics and safety of a novel anti-HBs-enriched immunoglobulin in healthy volunteers after subcutaneous and intramuscular administration. Eur J Clin Pharmacol 62:511-512
40. Lee SK, Park JH, Joh JW et al (2000) Prophylaxis against hepatitis B recurrence following liver transplantation in HBs Ag (+) patients. Transplant Proc 32:2248
41. Avolio AW, Nure E, Pompili M et al (2008) Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches. Transplant Proc 40:1961-1964
42. Yilmaz N, Shiffman ML, Todd Stravitz R et al (2008) Prophylaxis against recurrence of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. Liver Int 28:72-78
43. Gugenheim J, Baldini E, Ouzan D et al (1997) Absence of initial viral replication and long-term high dose immunoglobulin administration improve results of hepatitis B virus recurrence prophylaxis after liver transplantation. Transplant Proc 29:517
44. Markowitz JS, Martin P, Conrad AJ et al (1998) Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28:585-589
45. Ishitani M, McGory R, Dickson R et al (1997) Retransplantation of patients with severe posttransplant hepatitis B in the first allograft. Transplantation 64:410-414
46. Adler R, Safadi R, Caraco Y et al (1999) Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Hepatology 29:1299-1305
47. Neff GW, Sherman KE (2004) Post-transplant hepatitis: HCV and HBV. Current Hepatitis Reports 3:98-104
48. Angeli P, Scaglione F (2008) Nephrotoxicity of intravenous immunoglobulin in the setting of liver transplantation or HBVLangenbecks related cirrhosis: an undervalued topic. Minerva Gastroenterol Dietol 54:259-275
49. Habib S, Shaikh OS (2007) Hepatitis B immune globulin. Drug Today 43:379
50. Golling M, Arnold JC, Rudek B et al (1998) HBV prophylaxis: cost/benefit analysis following liver transplantation for HBVpositive liver cirrhosis. Transplant Proc 30:3316-3317
51. Angus PW, Patterson SJ (2008) Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transplant 14:S15-S22
52. Deeney HN, Dusheiko GM (2009) Lamivudine combined with hepatitis B immunoglobulin in for prophylaxis of hepatitis B recurrence after liver transplantation: time for a change? Transpl Int 22:385-386
53. Rosenau J, Kreutz TH, Kujawa M et al (2007) HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. J Hepatol 46:635-644
54. Lenci I, Tisone G, Di Paolo D et al (2008) Total and covalently closed circular DNA detection in post liver transplant liver biopsies of HBV positive patients who underwent liver transplantation with undetectable viraemia. Hepatology 44:573A
55. Dumortier J, Chevallier P, Scoazec JY et al (2003) Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long term results. Am J Transplant 3:999-1002
56. Faria LC, Gigou M, Roque-Afonso AM et al (2008) Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 134:1890-1899
57. Zoulim F, Radenne S, Ducert CH (2008) Management of patients with decompensated hepatitis B virus association cirrhosis. Liver Transplant 14:S1-S7
58. Cooreman MP, Leroux-Roels G, Paulij WP (2001) Vaccine-and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 8(3):237-247
59. Degertekin B, Han SH, Keeffe EB et al (2010) The NIH HBVOLT Study Group. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplant ation. Am J Transplant 10:1823-1833
60. Dan YY, Wai C H T, Yeoh K H G et al (2006) Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transplant 12:736-746
61. Han SH, Martin P, Edelstein M et al (2003) Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transplant 9:182-187
62. Di Paolo D, Tisone G, Piccolo P et al (2004) Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 77:1203-1208
63. O'Grady JG (1997) Clinical economics review: liver transplantation. Aliment Pharmacol Ther 11:445-451
64. Jiao ZY, Jiao Z (2007) Prophylaxis of recurrent hepatitis b in Chinese patients after liver transplantation using lamivudine combined with hepatitis B immune globulin according to the titer of antibody to hepatitis B surface antigen. Transplant Proc 39:1533-1536
65. Saab S, Ham MY, Stone MA et al (2009) Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transplant 15:413-420
66. Gane EJ, Angus PW, Strasser S et al (2007) Lamivudine plus low dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 132:931-937
67. Jiang L, Jiang LS, Cheng NS et al (2009) Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 15:2489-2499
68. Dienstag JL, Perrillo RP, Schiff EF et al (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-1661
69. Zoulin F, Trepo C (2000) Is lamivudine effective on precore/core promoter mutants of hepatitis B virus? Hepatology 32:1172-1174
70. Chen RY, Edwards R, Shaw T et al (2003) Effect of the G1896 A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 37:27-35
71. Fung J, Lai CH-L, Tanaka Y et al (2009) The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBe Ag seroconversion. Am J Gastroenterol 104:1-7
72. Wai CT, Lim SG, Tan KC (2001) Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients in Singapore. Gut 48:581
73. Fontana RJ, Keeffe EB, Carey W et al (2002) Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transplant 8:433-439
74. Tenney DJ, Pokornowski K, Rose R et al (2008) Entecavir at five years shows long term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2:S76-S77
75. Van Bommel F, Zollner B, Sarrazin C et al (2006) Tenofovir for patients with lamivudine-resistant hepatitis B virus infection and high HBV DNA level during adefovir therapy. Hepatology 44:318-325
76. Lai CL, Leung N, Teo EK et al (2005) A 1-year trial of telbivudine, lamivudine and the combination in patients with hepatitis B antigen-positive chronic hepatitis B. Gastroentrology 129:528-536
77. Angus PW, Patterson SJ, Strasser SI et al (2008) A randomized study of adefovir dipivoxil in place of HBIg in combination with lamivudine as post liver transplantation hepatitis B prophylaxis. Hepatology 48:1460-1466
78. Freshwater DA, Dudley T, Cane P et al (2008) Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation 85:1105-1111
79. Schiff E, Lai CL, Hadziyannis S et al (2007) Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transplant 13:349
80. Schiff ER, Lai CL, Hadziyannis S et al (2003) Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in preand post-liver transplantation patients. Hepatology 38:1419
81. Chang TT, Gish RG, De Man R et al (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354:1001
82. Kuo A, Dienstag JL, Chung RT (2004) Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2:266
83. Hou J, Yin YK, Xu D et al (2008) Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 47:447-454
84. Lai CL, Gane E, Liaw YF et al (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357:2576-2588
85. Lee PH, Hu RH, Tsai MK et al (2000) Liver transplantation for patients with hepatitis B: prevention of hepatitis B recurrence by intravenous antihepatitis B immunoglobulin and lamivudine. Transplant Proc 32:2245-2247
86. Engler S, Sauer P, Klar E et al (2002) Prophylaxis of hepatitis B recurrence after liver transplantation with lamivudin and hepatitis B immunoglobulin. Transplant Proc 34:2285-2287
87. Steinmuller T, Seehofer D, Rayes N et al (2002) Increasing applicability of liver transplantation for patients with hepatitis Brelated liver disease. Hepatology 35:1528
88. Katze L, Paul M, Guy D et al (2008) Prevention of recurrent hepatitis B virus infection after liver transplantation. HBIg antiviral drugs or both? Systematic review and meta analysis. Hepatology 48:573A
89. Rizzetto M, Marzano A (2000) Posttransplantation prevention and treatment of recurrent hepatitis B. Liver Transplant 6(Suppl 2):S47-S51
90. Avery PK, Michaels M (2008) Update on immunizations in solid organ transplant recipients: what clinicians need to know? Am J Transpl 8:9-14
91. Gunther M, Neuhaus R, Bauer T et al (2006) Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients: antibody decline and booster vaccination with conventional vaccine. Liver Transplant 12:316-319
92. Di Paolo D, Lenci I, Trinito MO et al (2006) Extended doubledosage HBV vaccination after liver transplantation is ineffective in the absence of lamivudine and prior wash-out of human hepatitis B immunoglobulins. Dig Liver Dis 38:749-754
93. Rosenau J, Hooman N, Hadem J et al (2007) Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transplant 13:367-373
94. Rosenau J, Hooman N, Rifai K et al (2006) Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Euro Soc Organ Transplant 19:828-833
95. Bauer T, Günther M, Bienzle U et al (2007) Vaccination against hepatitis B in liver transplantation recipients: pilot analysis of cellular immune response shows evidence of HBs Ag specific regulatory T cells. Liver Transplant 13:434-442
96. Sanchez-Fueyo A, Rimola A, Grande L et al (2000) Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 31:496
97. Angelico M, Di Paolo D, Trinito MO et al (2002) Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 35:176
98. Cornberg M, Protzer U, Dollinger MM et al (2007) Prophylaxis, diagnosis and therapy of hepatitis-B-virus-(HBV-) infection: upgrade of the guideline, AWMF-Register 021/011. Z Gastroenterol 45:525-574
99. Cornberg M, Protzer U, Dollinger MM et al (2008) The German guideline for the management of hepatitis B virus infection. J Viral Hepatitis 15:1-20
100. Bienzle U, Gunther M, Neuhaus R et al (2003) Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 38:811-819
101. Chang SH, Suh KS, Yi NJ et al (2003) Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology 37:1329
102. Serrano B, Bayas JM, Bruni L et al (2007) Solid organ transplantation and response to vaccination. Vaccine 25:7331
103. Loinaz C, de Juanes JR, Gonzalez EM et al (1997) Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology 44:235
104. Dahmen U, Dirsch O, Li J et al (2004) Adoptive transfer of immunity: a new strategy to interfere with severe hepatitis virus reinfection after woodchuck liver transplantation. Transplantation 77:965-972
105. Shouval D (2007) Adoptive transfer of immunity to HBV in liver transplant patients: a step forward toward the proof of concept for therapeutic vaccination or a transient immunologic phenomenon? Liver Transplant 13:14-17
106. Luo Y, Lo CM, Cheung CK et al (2007) Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Transplant 13:71-79
107. Lo CM, Lau GK, Chan SC et al (2007) Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transplant 7:434-439
108. Vandepapeliere P, Lau GK, Leroux-Roels G et al (2007) Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25:8585-8597
109. Schumann A, Fiedler M, Dahmen U et al (2007) Cellular and humoral immune response to a third generation hepatitis B vaccine. J Viral Hepat 14:592-598
110. Protzer-Knolle U, Naumann U, Bartenschlager R et al (1998) Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27:254-263
111. Samuel D, Bismuth A, Serres C et al (1991) HBV infection after liver transplantation in HBsAg positive patients: experience with long-term immunoprophylaxis. Transplant Proc 23:1492-1494
112. Buti M, Mass A, Prieto M et al (2000) Rabdomized clinical trial of lamivudine vs. lamivudine+hepatitis B gammaglobulin in the prevention of HBV recurrence after liver transplant-preliminary results. Hepatology 32:217A
113. Roque-Afonso AM, Feray C, Samuel D et al (2002) Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 50:95-99
114. Roche B, Samuel D, Roque AM et al (1999) J Hepatol 30(Suppl 1):80
115. Yoshida EM, Erb SR, Partovi N et al (1999) Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low dose hepatitis B immune globulin. Liver Transplant Surg 5:520-525
116. Dodson SF, Bonham CA, Geller DA et al (1999) Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 68:1058-1061
117. Angus PW, McCaughen GW, Gane EJ et al (2000) Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post transplantation hepatitis B. Liver Transplant 6:429-433
118. Han SH, Ofman J, Holt C et al (2000) An efficacy and cost effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transplant 6:741
119. Anselmo DM, Ghobrial RM, Jung LC et al (2002) New era of liver transplantation for hepatitis B: a 17 year single-center experience. Ann Surg 235:611-619
120. Rosenau J, Bahr MJ, Tillmann HL et al (2001) Lamivudine and low dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role to transplantation as a risk factor for reinfection. J Hepatol 34:895-902
121. Marzano A, Salizzoni M, Debernardi-Venon W et al (2001) Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 34:903-910
122. Seehofer D, Rayes N, Steinmüller T et al (2002) Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance. Z Gastroenterol 40:795-799
123. Lee KW, Lee DS, Lee HH et al (2004) Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation. Transplant Proc 36:2311-2312
124. Ferretti G, Merli M, Ginanni Corradini S et al (2004) Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 36:535-538
125. Neff GW, O'Brien CB, Nery J et al (2004) Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transplant 10:1372-1378
126. Dickson RC, Terrault NA, Ishitani M et al (2006) Protective antibody levels and dose requirements for IV 5% Nabi hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transplant 12:124-133
127. Yan ML, Yan LN, Li B et al (2006) Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 5:360-363
128. Zheng S, Chen Y, Liang T et al (2006) Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transplant 12:253-258
129. Wong SN, Chu CJ, Wai CT et al (2007) Low risk of hepatitis B virus recurrence after withdrawal of long term hepatitis B immunoglobulin in patients receiving maintenance nucleoside analogue therapy. Liver Transplant 13:374-381
130. Akyildiz M, Karasu Z, Zeytunlu M et al (2007) Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 22:2130-2134
131. Iacob S, Hrehoret D, Matei E et al (2008) Costs and efficacy of "on demand" low-dose immunoprophylaxis in HBV transplanted patients: experience in the Romanian program of liver transplantation. J Gastrointestin Liver Dis 17:383-388
132. Woo HY, Choi JY, Jang JW et al (2008) Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. J Med Virol 80:1891-1899